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1. Introduction   
Over the last three decades, prenatal screening for Down syndrome and other chromosomal 
abnormalities has become routine during antenatal care. Down syndrome screening has 
changed from the second to the first trimester of pregnancy because of the higher detection 
rate and earlier diagnosis. Second-trimester screening, based on the combination of maternal 
serum human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), and unconjugated 
estradiol (uE3) as a function of maternal age, yields a detection rate of 60% with a false-
positive rate (FPR) of 5% (Wald et al., 1988). In standard practice, first-trimester screening, 
which combines maternal age, nuchal translucency thickness (NT), and maternal serum free 
beta-human chorionic gonadotropin (fβ-hCG), and pregnancy-associated plasma-protein-A 
(PAPP-A), can achieve a detection rate 90% with a FPR of 5% (Snijders et al., 1998; 
Nicolaides, 2004; Wojdemann et al., 2005; Spencer, 2007).  
Down syndrome screening among women pregnant after assisted reproductive technologies 
(ART) is complicated by several factors. Pregnancies conceived after ART represent a group of 
high-risk pregnancies, which carry a higher psychological and financial burden compared to 
spontaneous pregnancies (Oddens et al., 1999). The proportion of women aged 35 years or 
more is higher in ART pregnancies, therefore, they a more likely to be carrying a child affected 
by Down syndrome (Geipel et al., 1999; Pinborg et al., 2004; Weisz and Rodeck, 2006, Gjerris et 
al., 2008). Studies have also shown that foetuses conceived after intracytoplasmic sperm 
injection (ICSI) are known to have an increased risk of chromosomal aberrations (Aboulghar et 
al., 2001; Bonduelle et al., 2002; Jozwiak et al., 2004; Gjerris et al., 2008). Pregnancies conceived 
after ART are also associated with a higher rate of multiple pregnancies (Weisz and Rodeck, 
2006, Gjerris et al., 2008). Maternal and fetal complications, such as foetal growth restriction, 
preeclampsia, preterm birth, congenital abnormalities, and low birth weight occur more often 
in assisted reproduction pregnancies (Helmerhorst et al., 2004; Amor et al., 2009; Williams and 
Sutcliffe, 2009; Henningsen et al., 2011). Women who have conceived after assisted 
reproductive techniques usually prefer to avoid invasive diagnostic procedures, such as 
amniocentesis and villus biopsy, due to the risk of miscarriage. Rather, they choose non-
invasive screening before making a decision about invasive testing (Meschede et al., 1998; 
Schover et al., 1998; Geipel et al., 1999; Geipel et al., 2004).  
Pregnancies conceived by assisted reproduction techniques have also been reported to be 
associated with changes in the biochemical parameters of screening for Down syndrome, 
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leading to an increased false-positive rate in the second trimester (Barkai et al., 1996; Ribbert 
et al., 1996; Frishman et al., 1997; Wald, 1999; Raty et al., 2002: Lambert-Messerlian et al., 
2005). The effect of ART on first-trimester Down syndrome screening has been examined, 
but the results are inconclusive. The majority of the studies have reported that nuchal 
translucency screening is not affected by the mode of conception (Liao et al., 2001; Nieminen 
et al., 2001; Wojdemann et al., 2001; Orlandi et al., 2002; Ghisoni et al., 2003; Lambert-
Messerlian et al., 2006; Matilainen et al., 2011). Yet, some studies suggested that NT 
measurements are altered in pregnancies conceived with ART (Maymon et al., 2002; Hui et 
al., 2005; Amor et al., 2009; Gjerris et al., 2009). Several studies have found that serum 
marker levels, especially PAPP-A levels, seem to be altered in ART pregnancies, leading to 
the higher false-positive rate, whereas other studies have been unable to confirm this.    
In this chapter, we present the recent findings of first-trimester Down syndrome screening 
in singleton and twin pregnancies conceived after assisted reproductive technologies.    
2. The effect of ART on nuchal translucency thickness and other ultrasound 
markers 
Measurement of nuchal translucency thickness as a single marker may be the most effective 
screening test, and is thought to be least affected by the mode of conception. Down 
syndrome screening, which combines maternal age and fetal nuchal translucency thickness 
measurement, can achieve a detection rate of 75 - 80% with a false-positive rate of 3 - 5% 
(Kagan et al., 2010). There are several studies which have been examined, whether the 
nuchal translucency measurements are altered in pregnancies conceived by ART.  
In the study by Gjerris et al., (2009) the median NT in entire ART group (n = 992) was 
smaller when compared with spontaneous pregnancies (n = 2532). They also found that the 
mode of the conception had an effect on NT:  the nuchal translucency thickness was thinner 
in in-vitro fertilization (IVF) cases when compared with intracytoplasmic sperm injection 
(ICSI) cases. They also found that a smaller nuchal translucency thickness was noted in 
pregnancies treated with a long protocol hormone treatment compared with those with the 
short hormone treatment protocol. There was not any obvious biological explanation for 
these findings; any significant differences might be due to chance as several statistical 
analyses were performed. Opposite findings were reported by Amor et al., (2009); they 
found that in ART pregnancies (n = 833) the nuchal translucency thickness was increased 
compared with the controls. There was no difference between IVF and ICSI group.   
In our own study (Matilainen et al., 2011), we investigated 282 pregnancies conceived after 
assisted reproductive technologies, and in which only one fetus was noted in early 
ultrasound examination, and who participated in first trimester combined screening. There 
were 24.783 spontaneous singleton pregnancies in our control group. Patients were divided 
into four groups according to the type of conception, as follows: controls, hormonally 
stimulated in-vitro fertilization or intracytoplasmic sperm injection group, spontaneous non-
stimulated frozen embryo transfer (FET) group, and hormonally stimulated FET group 
(HRT-FET). In our study population, NT or NT MoMs (multiples of the medians) were not 
significantly different between the different type of ART pregnancies and spontaneous 
pregnancies.  
The majority of the studies found no difference in the size of NT in ART pregnancies 
compared with spontaneous pregnancies (Liao et al., 2001; Nieminen et al., 2001; 
Wojdemann et al., 2001; Orlandi et al., 2002; Ghisoni et al., 2003; Lambert-Messerlian et al., 
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2006 and Matilainen et al. 2011), and no influence on the screening performance and the 
false-positive rate by compining maternal age and NT for Down syndrome risk assessment 
(Liao et al., 2001; Ghisoni et al., 2003; Bellver et al., 2005; Lambert-Messerlian et al., 2006; Tul 
and Novac-Antolic, 2006; Ancaert et al., 2008; Bender et al., 2010; Matilainen et al., 2011).  
Gjerris et al. (2008) found that gestational age dating in ART pregnancies either by the date 
of oocyte aspiration (DOA) or by crown-rump length differed significantly by 1.5 days. The 
gestational age was higher when it was dated according to CRL. The study group 
speculated that fetuses were larger than expected at the NT scan and their real biological 
gestational age was lower, therefore, a smaller NT MoM values were observed in assisted 
reproduction pregnancies (Gjerris et al., 2009). According to a mathematical stimulation 
method, the use of CRL or DOA for gestational age dating did not significantly influence the 
detection rate for Down syndrome (Gjerris et al., 2008).   
First-trimester screening, which combines maternal age, fetal nuchal translucency thickness, 
and maternal serum free β-hCG, and PAPP-A, can achieve the detection rate of 90% with the 
FPR of 5% (Snijders et al., 1998; Nicolaides, 2004; Wojdemann et al., 2005; Spencer, 2007). A 
further improvement in the screening performance can be achieved by including the 
assessment of additional, new ultrasound markers. These additional markers are the 
absence of the nasal bone, and the blood flow in the ductus venosus, and across the 
tricuspid valve. The absence of the nasal bone, reversed a-wave in the ductus venosus, and 
tricuspid regurgitation are observed in about 60, 65 and 55% of fetuses with Down 
syndrome and in 2.6, 3.2 and 0.9%, respectively, of euploid fetuses. The assessment of each 
of these sonographic markers into first-trimester combined screening, which uses maternal 
age, NT thickness, and maternal serum free β-hCG, and PAPP-A, can yields a detection rate 
of 93 - 96% with the false-positive rate of 2.5%. Screening for Down syndrome by maternal 
age, nuchal translucency thickness and either the ductus venosus, the nasal bone, or the 
tricuspid flow, at the risk cut-off of 1:100, identified 83, 85, and 85% of cases with false-
positive rate of 2.9, 2.7 and 2.7%, respectively (Kagan et al., 2010). Unfortunately, there are 
no studies concerning these new ultrasound markers in pregnancies conceived after ART.  
3. The effect of ART on first-trimester biochemical markers 
In pregnancies affected by Down syndrome the maternal serum level of PAPP-A is reduced 
to about half (Brambati et al., 1993) and the level of free β-hCG is about twice as high when 
compared with values in chromosomally normal pregnancies (Spencer et al., 1992). Maternal 
serum PAPP-A and free β-hCG values are affected by many variables, therefore, to estimate 
accurate patient-specific risks, adjustments in the measured free β-hCG and PAPP-A levels 
take into account their association with gestational age, maternal weight, ethnicity, and 
smoking status (Spencer et al., 1999a; Spencer et al., 2003b; Avgidou et al., 2005; Nicolaides 
et al., 2005). In addition, the mode of conception has an effect on maternal serum screening 
markers.  
Previous studies have shown that serum markers in ART pregnancies differ from natural 
conception in the second trimester, leading to an increased false-positive rate (Barkai et al., 
1996; Ribbert et al., 1996; de Graaf et al., 2000; Niemimaa et al., 2003). Most of the recent 
studies have reported that first-trimester serum markers are altered in pregnancies 
conceived after assisted reproduction, when comparing with spontaneous conception. Many 
studies have shown a reduction, especially in the PAPP-A levels, in ART pregnancies. In our 
own study (Matilainen et al., 2011), we investigated 282 pregnancies conceived after ART, 
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and in which only one fetus was noted in early ultrasound, and who participated in first 
trimester combined screening. The control group was comprised of 24.783 spontaneous 
singleton pregnancies.  We found a significant reduction in the PAPP-A concentration level 
in entire ART group when compared with controls. This is in agreement with most previous 
studies (Liao et al., 2001; Orlandi et al., 2002; Bersinger et al., 2004; Maymon et al., 2004; Hui 
et al., 2005; Tul and Novac-Antolic, 2006; Ancaert et al., 2008; Gjerris et al., 2009; Amor et al., 
2009).  
Some studies have found that PAPP-A levels are decreased in the subgroups of IVF (Liao et 
al., 2001; Tul and Novac-Antolic, 2006; Amor et al., 2009; Gjerris et al., 2009; Bender et al., 
2010; Engels et al. 2010) or ICSI (Ancaert et al., 2008; Amor et al., 2009; Gjerris et al., 2009; 
Bender et al., 2010; Engels et al., 2010).  However, few studies found no differences in the 
value of maternal serum PAPP-A levels in ART conceptions compared to controls (Ghisoni 
et al., 2003; Bellver et al., 2005; Lambert-Messerlian et al., 2006). The study by Kagan et al. 
(2008), which is the largest study so far, reported that PAPP-A levels were reduced 10% in 
pregnancies conceived after assisted reproduction (n = 2115), when compared to controls (n 
= 94.688). In our study (Matilainen et al., 2011), we found no statistically significant 
differences in pregnancies conceived after spontaneous FET or HRT-FET, compared with 
the control group. There are other studies reported that the median PAPP-A MoM level was 
not significantly reduced in FET pregnancies (Anckaert et al., 2008; Gjerris et al., 2009). 
There is also a study in which the median PAPP-A MoM levels were significantly reduced in 
ICSI pregnancies in the fresh and the frozen-thawed embryo subgroups and in the fresh 
embryo IVF subgroups as compared to controls (Hui et al., 2005). Amor et al. (2009) studied 
PAPP-A concentration levels in fresh embryo transfers (n = 773) and frozen embryo 
transfers (n = 573). PAPP-A levels were reduced in both subgroups when compared with 
spontaneous pregnancies. However, fresh embryo transfers were associated with 
significantly lower PAPP-A levels when compared with FET pregnancies.  
Studies concerning about the free β-hCG concentration levels in assisted reproduction 
pregnancies are contradictory. In our study (Matilainen et al. 2011), we found no difference 
in the median free β-hCG MoM concentrations in between the ART and control groups. This 
is in agreement with most previous studies (Orlandi et al., 2002; Tul et al. 2006; Bellver et al., 
2005;  Gjerris et al., 2009; Amor et al., 2009). Yet, there are some studies which have reported 
the free β-hCG levels to be increased in ART pregnancies (Niemimaa et al., 2001; Liao et al., 
2001; Ghisoni et al., 2003; Bersinger et al., 2004; Hui et al., 2005). One study even has 
reported slightly decreased free β-hCG levels in IVF pregnancies (Engels et al., 2010). 
The disintegrin and metalloproteinase domain 12 (ADAM12) is a further first-trimester 
serum marker for Down syndrome (Laigaar et al., 2003) and other chromocomal aberrations 
(Spencer & Cowans, 2007). There is only one study concerning the use of ADAM12 as a first- 
trimester Down syndrome screening marker in ART pregnancies (Laigaard et al., 2009). 
Study group found no alterations in ADAM12 serum marker levels in ART pregnancies 
when compared with spontaneous pregnancies.   
In our study, the odds ratios for a false-positive rate in the combined first-trimester 
screening for Down syndrome by maternal age, nuchal translucency, and PAPP-A, and free 
β-hCG, were not increased in women who conceived following ART, after adjustment for 
maternal age (Matilainen et al. 2011). This is in agreement with many other studies 
(Maymon and Shulman, 2001b; Liao et al., 2001; Wojdemann et al., 2001; Orlandi et al., 2002; 
Bellver et al., 2005). There are also studies which have reported higher FPR in the ART 
group even after adjustment for maternal age (Orlandi et al., 2002; Amor et al., 2009; Gjerris 
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et al., 2009). Tul and the study group (2006) found a higher FPR in pregnancies after ICSI. 
Amor et al. (2009) found that PAPP-A levels were reduced and FPR was higher, both in 
fresh and frozen-thawed embryos, but only in pregnancies in which the mother was 
administered hormone treatment around the time of embryo transfer. First-trimester Down 
screening which combines maternal age, NT, and biochemical markers may increase the 
false-positive result in ART pregnancies, therefore, it increase the likelihood of having 
amniocentesis or chorionic villus sampling. However, contradictory results from previous 
published works require larger studies. As more information accumulates on serum marker 
variations in ART pregnancies, procedure-specific medians for serum markers may need to 
correct changes in pregnancies conceived after ART. Table 1 summarizes the results of the 
previous studies.  
4. Possible explanations for altered serum marker levels in ART pregnancies 
There are many possible confounding factors, which could lead to contradictory results on 
maternal serum screening markers in pregnancies conceived after assisted reproductive 
techniques. Multiple corpora lutea and multiple implantation sites have been suggested to 
be the reason for either increased or decreased marker levels (Weisz et al., 2006). It has been 
recommended that abnormal marker levels could be due to the underlying subtle metabolic 
or genetic conditions that can also be the reason for infertility itself (Ribbert et al., 1996). It 
has also been suggested that lower PAPP-A levels in ART pregnancies might be the result of 
metabolic impairments related to infertility of the mother (Maymon and Shulman, 2002). 
However, Amor et al. (2009) found that PAPP-A levels were reduced, both in male-factor 
infertility, female-factor infertility, and the combination of female and male cause. Anckaert 
et al. (2008) found that PAPP-A values did not differ between male and female infertility. 
The same study group found higher median free β-hCG level values in non-male infertility 
compared with male infertility and spontaneous pregnancies.   
Also, a functional delay in fetal and placental development and the higher risk of obstetric 
complications associated with ART, can lead to changes in serum marker concentrations 
(Maymon et al., 2004; Helmerhorst et al., 2004; Hui et al., 2005, Williams et al., 2009; 
Henningsen et al., 2011). Studies have shown that low first-trimester PAPP-A levels 
indicates placenta-related disorders, such as fetal growth restriction, low birth weight, 
preeclampsia (Papageorghiou et al., 2007; Gagnon et al., 2008; Pihl et al., 2008; Goetzinger et 
al., 2010). Studies have also shown that maternal and fetal complications occur more often in 
assisted reproduction pregnancies (Helmerhorst et al., 2004; Amor et al., 2009; Williams et 
al., 2009; Henningsen et al., 2011). However, Amor et al. (2009) found that PAPP-A levels 
were reduced in ART pregnancies with or without pregnancy complications (e.g., 
preeclampsia or low birth weight). In other study by Zhong et al. (2010), ART pregnancies 
with low PAPP-A level values were at higher risk for small-for-gestational-age infants or 
preterm delivery less than 32 weeks of gestation when compared with spontaneous 
pregnancies with low PAPP-A values. 
Recent studies have suggested that vanishing twin might have the impact on serum marker 
level alterations. Spencer et al. (2010) found that in women with a second empty gestational 
sac, the median PAPP-A and free β-hCG values were not different from the median values 
in non-ART pregnancies. Yet, they found that median PAPP-A levels were significantly 
increased in pregnancies with a vanishing twin and a measurable crown-rump length. 










Free β-hCG PAPP-A 
Liao et al. (2001) 1233 161 (OI) äå äå 
  220 (IVF) ç è 
  30 (ICSI) äå è 
Wojdemann et al. (2001) 3026 63 (OI) äå äå 
 47 (IVF) äå äå 
Niemimaa et al. (2001) 4265 49 (IVF) äå ç 
Orlandi et al. (2002) 370 32 (IVF) äå è 
 42 (ICSI) äå äå 
Maymon and Shulman (2002) 285 71 (IVF) äå è 
Ghisoni et al. (2003) 435 145 (ART) ç äå 
Maymon and Shulman (2004) 1781 99 (IVF) N/A è 
Hui  et al. (2005) 401 92 (IVF) è è 
 57 (ICSI) äå è 
 54 (FET/IVF) äå äå 
 31 (FET/ICSI) äå è 
Bellver et al. (2005) 498 97 (OI) äå äå 
 47 (IVF) äå äå 
 222 (ICSI) äå äå 
 71 (OD/IVF) äå äå 
 119 (OD/ICSI) ç äå 
Lambert-Messerlian et al. (2006) 37 070 277 (IVF) ç è 
Tul and Novac-Antolic (2006) 914 130 (IVF) äå è 
Kagan et al. (2008) 97 294 2115 (IVF) è ç 
Gjerris et al. (2009) 2532 992 (ALL ART) äå ç 
 512 (IVF) äå ç 
 396 (ICSI) äå ç 
 84 (FET) äå äå 
Amor et al. (2009) 50 253 1739 (ALL ART) äå ç 
 654 (IVF) äå ç 





 573 (FET) äå ç 
  
Matilainen et al. (2011) 24 783 176 (IVF/ICSI) äå ç 
87 (FET) äå äå 
19 (HRT-FET) äå äå 
OI=ovulationinduction,
è=decreased,ç=increadec,äå=not different 
Table 1. Comparison of first trimester biochemical markers in singleton pregnancies 
achieved spontaneously and by assisted reproduction. 
that in their ART population vanished twins appear to increase the PAPP-A levels rather 
than decrease them. Gjerris et al. (2009) found no effect on PAPP-A and free β-hCG 
concentration values in ART pregnancies with an early vanishing twin. It is believed that 
vanished twins do not decrease the PAPP-A levels, in fact, they might have the opposite 
effect (Amor et al., 2009). 
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Maymon and Shulman (2002) suggested that a reduction in PAPP-A levels in pregnancies 
conceived after assisted reproduction might be an artefact of testing being undertaken at an 
earlier gestation. Amor et al. (2009) found no difference between ART and non-ART 
pregnancies in the timing of ultrasound examination or blood sampling. However, they did 
found a slightly greater crown-grump length for frozen-thawed embryos compared to fresh 
embryos. They suggested that this difference may reflect a longer in-vitro culture time for 
frozen-thawed embryos, but the difference would not affect the median PAPP-A MoM 
levels because these values are adjusted for gestational age. 
There are several studies that have suggested that exogenous hormone treatment is the main 
reason for reduced PAPP-A levels in ART pregnancies (Bersinger et al., 2004; Hui et al., 
2005a; Tul and Novak-Antolic, 2006; Amor et al., 2009). Amor et al. (2009) examined the 
effect of hormone treatment versus no hormone treatment irrespective of FET or fresh 
embryo transfer and found low PAPP-A levels in transfer cycles with any hormone 
treatment when compared with cycles without hormone treatment. They also found that 
PAPP-A levels were reduced regardless of the type of ovarian stimulation. In our study, we 
also found that PAPP-A concentration levels were reduced in hormonally-stimulated 
IVF/ICSI pregnancies, but there was no statistically significant difference in spontaneous 
FET pregnancies (Matilainen et al., 2011). Amor et al. (2009) suggested that administration of 
exogenous hormones interferes with the normal endocrine changes of early pregnancy, 
resulting in reduced PAPP-A levels. Tul and Novak-Antolic (2006) found significantly 
decreased PAPP-A concentration levels with increasing numbers of transferred embryos 
and also with increasing numbers of retrieved oocytes. The authors hypothesized that the 
number of oocytes retrieved reflected the number of corpora lutea in pregnancies, 
supported by their other finding that inhibin A, which is secreted by corpora lutea, was 
increased with decreasing PAPP-A. They suggested that inhibin A inhibits the secretion of 
PAPP-A.  However, Bender et al. (2010) found no correlation between PAPP-A and free β-
hCG values and the transfer of one, two or three embryos in assisted reproduction 
pregnancies. 
5. Down syndrome screening in multiple pregnancies 
Twin pregnancies are becoming more frequent in most developed countries due to the 
increased use of assisted reproductive technologies and advanced maternal age (Spencer 
2000). Approximately 25% of pregnancies arising from assisted reproduction are twins or 
higher order multiples.  Despite increasing use of elective single-embryo transfer, double or 
more embryo transfer was in 2004 occur in more than 80% of all ART procedures (Andersen 
et al., 2008).  
During the last three decades various methods of screening for Down syndrome were 
introduced in clinical practice, yet, specific problems were encountered when they were 
applied for twin pregnancies. Screening for Down syndrome in twin pregnancies is 
considered to be difficult because of the clinical, technical and ethical challenges posed for 
diagnosis and clinical management of such pregnancies (Cuckle, 1998; Spencer and 
Nicolaides, 2003).  
The value of the prenatal screening for Down syndrome by biochemical test in twins is 
limited because of the masking effect of normal co-twins and the difficulty of pinpointing 
the abnormal co-twin (Cuckle, 1998); therefore the ultrasound seems to be the better method 
for Down syndrome screening both for spontaneous and ART twin pregnancies (Maymon et 
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al., 2002).  On the basis of the observation that nuchal translucency thickness measurements 
were comparable in twins and singleton pregnancies affected by Down syndrome, the 
application of a combination of maternal age and NT measurement as the tool of assessing 
the risk of trisomy 21 has been advocated in twins (Pandya et al., 1995; Sebire et al., 1996). 
The same screening strategy has also been proposed for twins produced from ART 
pregnancies (Maymon et al. 1999). The detection rates for Down syndrome of 75 - 80% have 
been reported in twin pregnancies using maternal age and NT for risk calculation (Sebire et 
al. 1996; Kagan et al., 2007).   
Chorionicity has an impact on Down screening measurements and first-trimester evaluation 
in twins is not completed until an accurate chorionity determination is performed 
(Sepulveda, 1997). The majority of twin pregnancies conceived after ART are dichorionic, 
yet, the incidence of monochorionic twin pregnancies after ART has increased (Wenstrom et 
al., 1993). Chorionicity has an impact on the nuchal translucency thickness. In 
monochorionic twin pregnancies mean fetal nuchal translucency thickness and inter-twin 
nuchal translucency thickness were larger when compared with dichorionic twin 
pregnancies (Cheng et al., 2010). In monochorionic twins the increased nuchal translucency 
thickness and discordance of NT have been associated with adverse pregnancy outcome, 
such as perinatal death and twin-twin transfusion syndrome (El Kateb et al., 2007; Kagan et 
al., 2007). Several studies have reported that the median NT measurements did not differed 
in twin pregnancies conceived after ART when compared to spontaneous pregnancies 
(Goence et al., 2005; Hui et al., 2005; Maymon et al., 2005). It is recommended that for 
dichorionic twins each co-twin fetus is treated as a singleton and its risk is calculated using 
the published distribution of NT values for singleton pregnancies (Maymon et al. 2005). In 
monochorionic twins, Down syndrome screening is provided by risk calculation based on 
the average nuchal translucency thickness measurement of two fetuses (Vandecruys et al., 
2005).  
Adding the PAPP-A and free β-hCG level measurements to nuchal translucency thickness in 
twin pregnancies may improve the detection rate about 5 - 6% (Spencer and Nicolaides, 
2003), but helped mainly to reduce the higher FPR (Goence et al, 2005, Chasen et al., 2007). 
In twin pregnancies interpreting all the results of these screening markers is more difficult 
because the serum marker concentration relates to the pregnancy, while each NT 
measurement is fetus-specific (Maymon et al., 2005). Chorionity is suggested to have an 
impact on maternal serum marker levels: one study reported lower PAPP-A levels but 
indifferent free β-hCG values in monochorionic twin pregnancies when compared with 
dichorionic pregnancies (Spencer et al., 2008). In other study both markers were decreased 
in monochoric twin pregnancies (Liskens et al., 2009). In two studies, where no 
differentiation of chorionicity was made, no differences were found in maternal serum 
concentrations between assisted twin pregnancies and controls (Orlandi et al., 2002; Gonce 
et al., 2005). It is recommended that when invasive testing is indicated, NT alone is the 
screening method women should be counseled to choose, because ultrasound is the best 
mean of specifically locating the affected co-twin (Spencer and Nicolaides, 2003).     
6. Conclusion 
Pregnancies conceived after ART represent a group of high-risk pregnancies, which carry a 
higher psychological and financial burden compared to spontaneous pregnancies (Oddens 
et al., 1999). ART pregnancies differ from spontaneous pregnancies in many aspects, 
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therefore, Down screening among women pregnant after ART is more complicated. The 
proportion of women aged 35 years or more is higher in ART pregnancies, therefore, a risk 
of women having a child affected by Down syndrome is also a higher (Geipel et al., 1999; 
Pinborg et al., 2004; Weisz and Rodeck, 2006, Gjerris et al., 2008). Risk of chromosomal 
aberrations is increased in pregnancies conceived after intracytoplasmic sperm injection 
(Aboulghar et al., 2001; Bonduelle et al., 2002; Jozwiak et al., 2004; Gjerris et al., 2008). The 
proportion of multi-fetal pregnancies is higher in pregnancies conceived after assisted 
reproduction (Weisz and Rodeck, 2006, Gjerris et al., 2008). Also fetal and maternal 
complications occur more often in assisted reproduction pregnancies (Helmerhorst et al., 
2004; Amor et al., 2009; Williams and Sutcliffe, 2009; Henningsen et al., 2011). The uptake of 
amniocentesis and villus biopsy is believed to be lower, because of the higher risk of 
miscarriage. Women pregnant after ART rather choose non-invasive Down screening before 
making a decision about invasive testing. (Meschede et al., 1998; Schover et al., 1998; Geipel 
et al., 1999; Geipel et al., 2004).  
A number of different first-trimester ultrasound and biochemical markers have been 
validated in first-trimester screening for Down syndrome. Method of choice in first-
trimester Down screening is combined screening, which measures maternal serum levels of 
free β-hCG and PAPP-A at 9 – 12 weeks of gestation and nuchal translucency by ultrasound 
at 11 – 13 weeks gestation. These measurements are combined with maternal age, weight, 
and gestational age to produce an risk estimate of fetus having a Down syndrome (Wald et 
al., 2003). For pregnancies with increased risk, an invasive procedure can be offered.  
Measurement of fetal nuchal translucency thickness is the most investigated screening 
method and it is believed to be least affected screening method in ART pregnancies. Some 
studies have reported a small deviation of NT measurements in pregnancies conceived after 
assisted reproduction, but these alterations did not influence overall screening performance. 
The majority of the studies found no difference in NT measurements in ART pregnancies 
compared with spontaneous conceptions (Liao et al., 2001; Nieminen et al., 2001; 
Wojdemann et al., 2001; Orlandi et al., 2002; Ghisoni et al., 2003; Lambert-Messerlian et al., 
2006 and Matilainen et al. 2011) and no influence on the screening performance and the 
false-positive rate by combining maternal age and NT for Down syndrome risk assessment 
(Liao et al., 2001; Ghisoni et al., 2003; Bellver et al., 2005; Lambert-Messerlian et al., 2006; Tul 
and Novac-Antolic, 2006; Ancaert et al., 2008; Bender et al., 2010; Matilainen et al., 2011). The 
use of new sonographic markers, such as the absence of the nasal bone, has not been 
explored in ART pregnancies.  
Several studies have reported that first-trimester maternal serum free beta-human chorionic 
gonadotropin and pregnancy-associated plasma protein-A levels are altered in ART 
pregnancies and might increase the false-positive rate. The reasons behind these alterations 
are not unambiguous. It has been suggested that e.g. exogenous hormone treatment, 
functional delay in fetal, and placental development and the higher risk of obstetric 
complications associated with ART can lead to changes in serum marker concentrations.     
Pre- and post-test counseling for women carrying ART-pregnancies is extremely important. 
Further studies should be determined the viability of altering the risk calculation for 
pregnancies conceived after ART.   
Twin pregnancies are becoming more frequent in most developed countries due to the 
increased use of assisted reproductive technologies and advanced maternal age (Spencer 
2000). Down screening in twin pregnancies is considered to be difficult because of the 
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clinical, technical and ethical challenges posed for diagnosis and clinical management of 
such pregnancies (Cuckle, 1998; Spencer and Nicolaides, 2003). In twin pregnancies 
chorionicity is an important confounding variable. It is recommended that for dichorionic 
twins, each co-twin fetus should be treated as a singleton and its risk should be calculated 
using the published distribution of NT values for singleton pregnancies (Maymon et al. 
2005). In monochorionic twins, Down syndrome screening is provided by risk calculation 
based on the average nuchal translucency thickness measurement of two fetuses 
(Vandecruys et al., 2005). 
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